Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

pembrolizumab

June 23, 2020

Oncology Trials Could Benefit From Increased Data on Tobacco Use

By

Industry News & Regulatory Approvals

By Leah Lawrence Posted: June 24, 2020 As part of its declaration on tobacco cessation after cancer diagnosis, the IASLC recommended that smoking status, both initially and during the study, […]
June 23, 2020

Single-Agent Pembrolizumab Active Against STK11- and KEAP1- Mutated NSCLC According to KEYNOTE-042 Analysis

By

Meeting News

By Kara Nyberg, PhD Posted: June 24, 2020 Genomic alterations in STK11 and KEAP1 represent two of the most common and potent contributors to a cold tumor immune microenvironment in […]

April 16, 2020

U.S. Drug Approvals: 2010 – 2020

By

Evolving Standards of Care

Posted: April 16, 2020
April 15, 2020

Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade

By

Kara Nyberg, PhD

Evolving Standards of Care

By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field […]
April 15, 2020

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

By

Diagnostic Oncology

By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […]

February 11, 2020

Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

By

Systemic, Targeted, & Immune Therapies

This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status. […]

December 10, 2019

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

By

Uncategorized

By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated […]
December 10, 2019

Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data

By

Evolving Standards of Care

Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. […]
November 11, 2019

2019 IASLC World Conference on Lung Cancer Updates

By

Meeting News

Posted: November 12, 2019 More than 7,700 delegates from around the world attended the IASLC 2019 World Conference on Lung Cancer (WCLC). With sessions and workshops on every aspect of […]